Satoru Yamakawa Selected Research

esaxerenone

1/2022	Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.
1/2021	Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
1/2021	Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
1/2020	[Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro® tablets 1.25 mg, 2.5 mg, 5 mg)].
1/2020	Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
12/2019	Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
1/2019	Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Satoru Yamakawa Research Topics

Disease

6	Hypertension (High Blood Pressure) 01/2022 - 12/2019
6	Essential Hypertension 01/2022 - 01/2019
3	Hyperkalemia 01/2021 - 12/2019
3	Neoplasms (Cancer) 07/2004 - 01/2002
2	Albuminuria 01/2021 - 01/2020
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2020
2	Neoplasm Metastasis (Metastasis) 07/2004 - 09/2003
1	Hyperaldosteronism (Conn Syndrome) 01/2021
1	Proteinuria 01/2020

Drug/Important Bio-Agent (IBA)

7	esaxerenoneIBA 01/2022 - 01/2019
6	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022 - 01/2019
3	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 12/2019
3	Eplerenone (Inspra)FDA LinkGeneric 01/2021 - 01/2020
2	SaltsIBA 01/2020 - 01/2020
2	PotassiumIBA 01/2020 - 12/2019
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 07/2004 - 09/2003
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022
1	pro-brain natriuretic peptide (1-76)IBA 01/2022
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 12/2019
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 07/2004
1	Collagen Type I (Type I Collagen)IBA 07/2004
1	Matrix Metalloproteinases (MMPs)IBA 09/2003
1	PolyphenolsIBA 09/2003
1	progelatinaseIBA 09/2003
1	TeaIBA 09/2003
1	Peptides (Polypeptides)IBA 01/2002
1	EpitopesIBA 01/2002
1	Alanine (L-Alanine)FDA Link 01/2002

Therapy/Procedure

2	Therapeutics 01/2021 - 12/2019